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High-altitude illness, as a result of free-radicalmediated inflammatory injury, has an impact on the increase in capillary permeability. 1, 2 Oxidative stress in subjects exposed to high altitude would be associated with hypoxia and ischemia-reperfusion injury. 3 This damage to the biological system influences immune function and enhances susceptibility to infection and/or delays recovery from altitude illness. 4 Highaltitude illness occurs in subjects who travel too high, too fast, and presents with headache, nausea, anorexia, fatigue, lassitude, and even death. 5 Increased oxidative stress and reduced antioxidant defense were observed in animals, with exposure to a simulated milieu of high altitude. 6 In addition, localized free radical generation caused by skeletal muscle damage may mediate vascular damage of the blood-brain barrier and contribute to the pathophysiology of acute mountain sickness (AMS). 7, 8 Furthermore, the erythropoietin (EPO) response to hypoxia was increased by altitude acclimatization. 9 Thus, we hypothesized that the altitude-oxidative stress and EPO response would be associated with the presence or absence of AMS in subjects at high altitude. The present study was designed to compare nonspecific clinical symptoms at altitude with the changes in oxidative stress. To explore the dynamics of free radical generation, we included 29 healthy subjects exposed to altitude without strenuous physical exercise. The association of oxidative stress and the EPO response was also investigated in subjects with and without AMS.
Materials and methods

Subjects
The research was carried out according to the principles of the Declaration of Helsinki and was approved by the Human and Ethics Committee of Taipei Veteran General Hospital. Informed consent from each individual was obtained. We enrolled 29 healthy volunteers. None had received oral antioxidants or had clinical evidence of hepatitis B or C, systemic diseases, immunological disorder, or active infection.
The survey of acute mountain sickness was based on the Lake Louise Score (LLS) included the standardized Lake Louise Self-report Questionnaire.
Blood collection and plasma preparation
To avoid the effect of strenuous physical exercise on the generation of free radicals, subjects spent about 8 hours car-driving each day, during the experimental period of 3 days. Baseline blood samples were obtained using heparinized syringes. After arriving at an altitude of 2000 and 3000 m, they stayed at that altitude for two hours prior to testing. The blood, collected as previously described, was transferred to 2-mL Eppendorf tubes, and was separated by centrifugation at 4,500 rpm for 10 minutes. Plasma was collected and stored immediately at 4 for subsequent biochemistry and malonaldehyde (MDA) assays.
Measurement of malonaldehyde
The principle of the method was based on the spectrophotometric measurement of the colour change during the reaction of malondialdehyde (MDA) with thiobarbituric acid (TBA); forming a MDA-TBA2 complex that absorbs strongly at 532 nm. The concentration of TBA reactive substances was calculated by the absorbance coefficient of MDA-TBA complex and expressed in nmol/mL. In brief, 2,6-Di-tert-butyl-4-methylphenol (BHT) 0.25 g was prepared to a final 50 ml of ethanol. 1 mL plasma sample was added to 0.25 mL BHT solution, and was then mixed with 1mL 20% trichloroacetic acid. The mixture was centrifuged at 13000 rpm for 5 min, 1.2 mL of the supernatant was transferred to another Eppendorf tube, followed by adding 0.5 mL of TBA. The mixture was heated in boiling water for 15 min, transferred to a disposable cuvette (Hellma 104-QS, German, 1400 μL) and left to stand at room temperature. MDA alone was used as the blank solution in each experiment. Absorbance, at a wavelength of 532 nm, was measured by spectrophotometry after the testing samples cooled.
Statistical analysis
Experimental data are reported as mean ± SEM. P < 0.05 was considered statistically significant. The difference between the 2 groups was determined by Student's unpaired t test. Standard regression analysis and Pearson r correlation coefficients were used to determine the relationships between MDA and EPO/ferritin concentration.
Results
The table shows the general and biochemical data of subjects with and without acute mountain sickness. EPO and Ferritin indicate the mean differences of EPO and ferritin levels detected between the baseline and at an altitude of 3000 m. Subjects fulfilling the criteria of AMS presented with headache, all at the altitude of 3000 m. There were no differences in EPO and Ferritin between these 2 groups.
Changes in EPO and Ferritin during increase in altitude
During the study periods, plasma ferritin level was relatively stable without differences in all studied subjects (Fig 1A and 1B) . Response to a rise in altitude at 3000 m, the change of mean plasma ferritin level showed insignificant increases in both 2 groups with and without AMS (Table) . In contrast, plasma EPO increased at an altitude of 3000 m and after returning to sea level (Fig 2; Figure 3 illustrates the dynamic curve of plasma MDA level, expressed as the value of OD532. At a height of 3000 m, plasma MDA level was elevated compared with that at baseline and 2000 m altitudes in both groups of subjects with and without AMS ( Along with a rise in altitude, the MDA oxidative stress of the subjects was not correlated with changes in EPO (r 2 = 0.0728, P = 0.1096; Fig 4) , and ferritin (r = -0.008545, P = 0.9275).
Changes in MDA concentration during increase in altitude
Discussion
High altitude oxidative stress, related to hypoxia, may link the development of the mountain sickness symptoms. 5, 10, 11 In our study, the oxidative stress of plasma MDA, in groups with and without AMS, had similar increases during the time spent at altitude. In the experimental periods, there were no changes in hematocrit (data not shown) or ferritin level between the two groups. However, the EPO level had increased from baseline on the 2 nd day after ascent to and staying at an altitude of 3000 m. The EPO responses to high altitude were not correlated with MDA levels. After returning to sea level, MDA decreased towards baseline in subjects without AMS, but remained steady in subjects with AMS. In response to high-altitude hypoxia, endogenous antioxidants and F2-isoprostanes level (products of lipid peroxidation) were elevated. 11 Other studies have demonstrated that subjects with AMS have a marked increase in inflammatory cytokine, but no differences in oxidative stress of F2-isoprostanes level compared with those without AMS. 12, 13 Our study showed similar results that oxidative stress in plasma MDA had increased in both groups with and without AMS, during exposure to high altitude. Hypoxia increases the production of EPO. We have characterized the time course of the EPO response in our study. Severe hypoxia provides a sufficient stimulus to increase EPO production within 4 h. 14 On ascent to 2000 m, the EPO response to hypoxia was modified and increased within 48 hours. 9,15 EPO attenuates apoptosis and has protective effects against ischemia-reperfusion injury via a free radical scavenger's modulator and antiinflammatory mediator. [16] [17] [18] Our study has shown the EPO level is increased at the 2 nd day at 3000 m. After returning to sea level, subjects without AMS had relatively lower MDA and higher EPO levels than those with AMS. This indicates that EPO may protect subjects from altitude illness. In response to hypoxicischemic preconditioning, EPO effect could stable free radical metabolism, enhance aerobic performance and attenuate the oxidative stress. [19] [20] [21] At high altitude, hypoxia might induce an inflammatory response with moderate systemic increases of these inflammatory markers. 13, 22 Inflammation and exposure to oxidative stress are believed to increase ferritin synthesis. 23 Ferritin, an iron-storage and acute-phase reactive protein, could also contribute to promote an increase in oxygen radical intermediates through Fenton complex. 24, 25 In our study, no changes of ferritin levels were noted despite the increase in MDA at altitude. There was no correlation between headache prevalence of AMS and ferritin, consistent with the previous report. 26 Therefore, analysis of ferritin could not account for altituderelated oxidative stress. Without any change of iron intake at altitude, a dramatic decrease in ferritin level has been reported. 9, 27 The different duration of exposure to high altitude in these previous studies may cause such discrepancy.
High altitude may promote free radical generation. Our results showed that high altitude-induced oxidative stress, detected by MDA assay, is not different between groups with and without AMS. On return to sea level, the oxidative stress burden of MDA decreased to the baseline level in subjects without AMS, but remained nearly steady in subjects with AMS. However, EPO level had the converse change with MDA. Whether the subjects with altitude illness exhibit delayed recovery from oxidative stress merits further investigation.
